2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.07C.11 Adjuvant Immunotherapy for Patients with Resectable NSCLC after Pathologic Complete Response

EP.07C.11 Adjuvant Immunotherapy for Patients with Resectable NSCLC after Pathologic Complete Response

Pdf Summary

This study investigates the efficacy of adjuvant immunotherapy in patients with resectable non-small cell lung cancer (NSCLC) who achieved a pathologic complete response (pCR) following neoadjuvant immunochemotherapy. Conducted at Xiangya Hospital, Central South University, China, the research evaluated patients with stage IB-IIIB NSCLC who, after achieving pCR, either received adjuvant immunotherapy for one year or did not receive further treatment.<br /><br />The study involved 63 patients, categorized into two groups: 36 patients received adjuvant immunotherapy, while 27 did not. Their primary outcome was disease-free survival (DFS). Over a median follow-up period of 24 to 25.5 months, results indicated that two patients (5.6%) in the adjuvant group experienced recurrence, compared to one patient (3.7%) in the non-adjuvant group. The DFS survival curves for both groups largely overlapped, showing no significant difference in outcomes (P=0.6325). Additionally, no severe treatment-related adverse events were reported in the adjuvant group.<br /><br />The preliminary findings suggest that, within the 24-month follow-up period, adjuvant immunotherapy did not substantially enhance DFS in patients who attained pCR post-neoadjuvant therapy. The study concludes that a longer follow-up period may be necessary to accurately compare DFS benefits between the groups.<br /><br />These findings add to the ongoing debate on the utility of adjuvant immunotherapy for patients with resected NSCLC who achieve pCR, indicating that further research with extended follow-up is necessary to determine its true benefit.

Asset Subtitle

Min Li

Meta Tag

Speaker Min Li

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

adjuvant immunotherapy

non-small cell lung cancer

NSCLC

pathologic complete response

neoadjuvant immunochemotherapy

disease-free survival

DFS

Xiangya Hospital

treatment outcomes

cancer recurrence